Article | Published:

Characterizing Recombinant Proteins

Bio/Technology volume 9, pages 921924 (1991) | Download Citation


Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , and (1989). Purity analysis of protein pharmaceuticals produced by recombinant DNA technology. Trends in Biotechnol. 7, 342–348.

  2. 2.

    , and (1988). Consideration of proteins and peptides produced by new technology for use as therapeutic agents. The Impact of Chemistry on Biotechnology.

  3. 3.

    Points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology. Office of Biologics Research and Review, Centre for Drugs and Biologics, FDA, 8800, Rockville Pike, Bethesda, MD 20205.

  4. 4.

    . et al. (1988). Characterization of recombinant human epidermal growth factor produced in yeast. Biochemistry 27: 797–802

  5. 5.

    et al. (1991). Amino acid analysis 1990: The third collaborative study from the ABRF. Techniques in Protein Chemistry II (Villafranca, J. ed.) Academic Press

  6. 6.

    (1991). A brief overview of mass spectrometric methods for the analysis of peptides and proteins. Techniques in Protein Chemistry II (Villafranca, J. ed.) Academic Press

  7. 7.

    (1991). NMR/X-ray workshop: an overview. Techniques in Protein Chemistry II (Villafranca, J. ed.) Academic Press.

  8. 8.

    , and (1991). Purification and production of therapeutic grade proteins. Bioprocess Technology (McGregor, W.C. ed.), 4, 29–54. Marcel Dekker.

Download references

Author information


  1. Michael J. Geisow is with Biodigm (U.K.), 64 Langdale Grove, Bingham, Nottinghamshire NG13 8SS, U.K.

    • Michael J. Geisow


  1. Search for Michael J. Geisow in:

About this article

Publication history



Further reading